TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

Go back to TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
(NASDAQ: RNAZ) Delayed: 1.71 +0.05 (3.01%)
Previous Close $1.66    52 Week High $ 
Open $1.62    52 Week Low $ 
Day High $1.76    P/E N/A 
Day Low $1.62    EPS $ 
Volume 5,737